For years, much of the public attention around cannabinoids has centered on consumer products, wellness applications, and legalization. Pharmaceutical development has followed a more demanding path, where new therapies must be supported by controlled studies, consistent manufacturing, and regulatory review before they can reach patients. That process has produced relatively few approved cannabinoid medicines, which makes each new development program notable for what it asks the science to prove.
CannEpil is now entering that process in a new area of medicine. Originally developed for people with drug-resistant epilepsy, the formulation is being evaluated for companion-animal oncology and chronic pain through a collaboration between Splash Beverage Group and Lupvindol Biosciences. Rather than adapting the product for the consumer pet market, the companies plan to pursue development through the FDA’s Center for Veterinary Medicine.
The effort will begin with the Investigational New Animal Drug process, during which developers work with regulators to establish a development plan, design studies, and determine what evidence will be needed to support a potential veterinary medicine. Dogs are expected to be the initial focus.
CannEpil combines cannabidiol and tetrahydrocannabinol isolates in a liquid formulation manufactured under European Union Good Manufacturing Practice standards. Its origins in human epilepsy place it in a different category from many cannabinoid products currently marketed for animals, which are generally sold as supplements or wellness products rather than developed as prescription medicines.
Building on Experience in Cannabinoid Pharmaceuticals
Developing a cannabinoid medicine requires expertise that extends beyond formulation science. Clinical study design, manufacturing consistency, regulatory strategy, and sustained engagement with the FDA all shape whether a product can move from early research into a formal approval pathway.
Splash selected Lupvindol in part because of its experience in that work. The company is led by Hunter Land, Ph.D., who served as GW Pharmaceuticals’ first full-time U.S. research and development employee and participated in the development of Epidiolex, the first FDA-approved plant-derived cannabinoid medicine, as well as Sativex. His background includes cannabinoid drug development, clinical protocol design, regulatory strategy, and commercialization planning.
That experience does not establish whether CannEpil will prove useful in dogs, but it gives the program access to leadership familiar with the practical demands of cannabinoid pharmaceutical development. Lupvindol will prepare the INAD submission, oversee study design, correspond with the FDA, and develop a potential application for conditional approval.
Splash will fund the work through milestone-based payments while retaining ownership of the study data, regulatory submissions, medical technology, and intellectual property created through the collaboration. The structure also preserves the company’s ability to decide later whether to pursue commercialization directly or work with an established animal-health pharmaceutical partner.
Looking Beyond Human Therapeutics
The decision to investigate CannEpil for canine cancer and chronic pain reflects the clinical realities of modern companion-animal care. Dogs are living longer, and veterinarians are spending more time managing illnesses that require sustained treatment rather than a single intervention.
Cancer is one of the clearest examples. According to the Veterinary Cancer Society, one in four dogs will develop cancer during their lifetime, while the National Cancer Institute estimates that roughly six million dogs are diagnosed with cancer each year in the United States. Chronic pain presents a related challenge because conditions such as arthritis and cancer can affect mobility, sleep, appetite, and quality of life over long periods.
Those needs help explain why cannabinoid development is moving beyond human therapeutics and consumer wellness products. CannEpil’s veterinary program is designed to determine whether an existing pharmaceutical formulation can be adapted for a new patient population through the same kind of structured scientific and regulatory work expected of other prescription medicines.
For the cannabinoid sector, that is the more important point. CannEpil is not being introduced as another pet CBD product. It is being tested as a pharmaceutical candidate, with its future resting on the quality of the evidence produced and whether that evidence supports a meaningful role in canine care.
